• Tuesday, July 17, 2018 @ 3:45 pm

Crenezumab's Second Phase 3 Trial (CREAD 2) Fully Recruited

Updates on AC Immune's Pipeline and Technology Platforms to be presented at the Alzheimer's Association International Conference in Chicago

Lausanne, Switzerland, July 17, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced that the second Phase 3 (CREAD 2) clinical trial of crenezumab, AC Immune's anti-Abeta antibody candidate for treatment of Alzheimer's disease, conducted by its partner Genentech, a member of the Roche Group, has completed global recruitment.

Prof. Andrea Pfeifer, CEO of AC Immune, commented: "We are very happy that the CREAD 2 recruitment has been completed ahead of schedule. This clearly shows the strong commitment of our partner Roche/Genentech to the development of crenezumab as a potential disease-modifying therapy for Alzheimer's disease - one of society's biggest healthcare challenges."

The following updates on AC Immune's advancement of its in-house and partnered product candidates and technology platforms including crenezumab, will be presented at the Alzheimer's Association International Conference (AAIC© 2018). The conference is the largest international meeting dedicated to advancing dementia science and takes place in Chicago, US, from July 22nd to 26th, 2018:


Program and Collaborator

Presentations and Timing

Tau PET Imaging agent /


Clinical Update: 18f-PI-2620, a Next Generation Tau PET Agent Evaluated in Subjects with Alzheimer's Disease and Progressive Supranuclear Palsy

Poster - July 21 / 12:30pm - 1:45pm (CDT)

Session: IC-P-220 / Hall: F1

Crenezumab /

Baseline characteristics from a phase 3 trial of crenezumab in prodromal to mild Alzheimer's disease (CREAD)

Oral presentation - July 22 / 8:45pm - 9:00pm (CDT)

Session: O1-02-04 / Room: 183

Alpha-synuclein PET tracers/ AC Immune

Novel alpha-synuclein Positron Emission Tomography (PET) tracers for the Diagnosis of Parkinson's Disease

Oral presentation - July 25 / 3:15pm - 3:30pm (CDT)

Session: DT-01-06 / Hall: W375 E

Crenezumab /

Target Engagement in an AD Trial: Crenezumab Lowers Aß Oligomer Levels in CSF

Oral presentation - July 25 / 4:45pm - 5:00pm (CDT)

Session: DT-01-03 / Hall: W375 E


About Crenezumab

Crenezumab is an anti-Abeta antibody discovered by AC Immune using its SupraAntigen(TM) technology platform and out-licensed to Genentech, a member of the Roche group, in 2006 as a potential therapy for Alzheimer's disease. Crenezumab is a fully humanized IgG4 monoclonal antibody that binds all forms of misfolded Abeta proteins, but especially to Abeta oligomers, to prevent and break up Abeta aggregation and promote Abeta disaggregation. The IgG4 subclass has reduced effector function, allowing microglia to clear Abeta from the brain while minimizing an inflammatory response.

Roche/Genentech is currently evaluating the clinical efficacy and safety of crenezumab in two Phase 3 clinical trials, CREAD 1 and 2, in 750 participants each trial with prodromal or mild Alzheimer's disease, which started in the first quarter of 2016 and the first quarter of 2017, respectively. CREAD 1 was fully recruited in the fourth quarter of 2017 and CREAD 2 completed global recruitment in July 2018. In addition, crenezumab was chosen by an international panel of experts, including the US National Institutes of Health, for use in a first-ever prevention trial in Alzheimer's disease in a large extended family in Colombia (API ADAD) in 2012.

You may also be interested in